Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “overweight” rating reissued by stock analysts at Piper Jaffray Companies in a research report issued to clients and investors on Tuesday, August 1st. They currently have a $557.00 price target on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target points to a potential upside of 19.02% from the stock’s previous close.
REGN has been the subject of a number of other reports. BMO Capital Markets lifted their price objective on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a “hold” rating in a report on Monday, May 15th. Vetr downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 price target for the company. in a research note on Monday, April 24th. UBS AG set a $489.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, May 5th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 14th. Finally, Canaccord Genuity set a $484.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, June 20th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $495.59.
Shares of Regeneron Pharmaceuticals (NASDAQ REGN) opened at 467.98 on Tuesday. Regeneron Pharmaceuticals has a 52 week low of $325.35 and a 52 week high of $543.55. The company has a market capitalization of $49.62 billion, a PE ratio of 46.95 and a beta of 1.66. The company has a 50 day moving average price of $489.51 and a 200 day moving average price of $430.92.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same period in the previous year, the business earned $2.82 EPS. Regeneron Pharmaceuticals’s revenue was up 21.2% compared to the same quarter last year. On average, equities research analysts expect that Regeneron Pharmaceuticals will post $14.85 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This story was first published by BNB Daily and is the sole property of of BNB Daily. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.baseball-news-blog.com/2017/08/19/regeneron-pharmaceuticals-inc-regn-stock-rating-reaffirmed-by-piper-jaffray-companies-updated-updated.html.
In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 9,295 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $458.14, for a total transaction of $4,258,411.30. Following the completion of the sale, the chairman now directly owns 414,156 shares of the company’s stock, valued at $189,741,429.84. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Neil Stahl sold 8,306 shares of the stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $532.55, for a total transaction of $4,423,360.30. Following the completion of the sale, the executive vice president now directly owns 43,950 shares of the company’s stock, valued at $23,405,572.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 84,404 shares of company stock valued at $40,303,792. 10.40% of the stock is owned by corporate insiders.
Several hedge funds have recently made changes to their positions in REGN. FMR LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after buying an additional 416,192 shares during the period. BlackRock Inc. boosted its position in Regeneron Pharmaceuticals by 0.7% in the second quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock valued at $3,039,305,000 after buying an additional 41,406 shares during the last quarter. Wellington Management Group LLP boosted its position in Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock valued at $2,377,590,000 after buying an additional 446,850 shares during the last quarter. Vanguard Group Inc. boosted its position in Regeneron Pharmaceuticals by 2.9% in the second quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock valued at $2,588,533,000 after buying an additional 148,962 shares during the last quarter. Finally, State Street Corp boosted its position in Regeneron Pharmaceuticals by 4.3% in the first quarter. State Street Corp now owns 3,380,151 shares of the biopharmaceutical company’s stock valued at $1,309,861,000 after buying an additional 139,602 shares during the last quarter. 67.16% of the stock is owned by hedge funds and other institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.